MULTIPLE ADMINISTRATIONS OF UMBILICUS DERIVED CELLS

• US 20090220995A1
• Filed: 02/28/2008
• Published: 09/03/2009
• Est. Priority Date: 02/28/2008
• Status: Abandoned Application

• Current Assignee: Christene Huang, David H. Sachs, Patricia S. Cho, Sicco Pompa
• Original Assignee: Christene Huang, David H. Sachs, Patricia S. Cho, Sicco Pompa
• Inventors: Huang, Christene, Cho, Patricia S., Sachs, David H., Pompa, Sicco
• Application Number:
  US12/039,480
• Publication Number:
  US 20090220995A1
• Time in Patent Office: Days
• US Class Current: 435/7.210
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 33/5088 of vertebrates

Abstract

A method to determine the optimal administration protocol of allogeneic donor tissue to treat a disease in a human, using an animal model of human disease.

Claims

1. A method to determine the optimal administration protocol of allogeneic donor tissue to treat a disease in a human, using an animal model of human disease, comprising the steps of:

a. Obtaining allogeneic donor tissue from a donor animal,

b. Inducing a disease state in a recipient animal,

c. Administering the allogeneic donor tissue to the recipient animal, and monitoring the immune response elicited by the allogeneic donor tissue, and

d. Altering the administration of the allogeneic donor tissue to reduce the immune response in the recipient animal.

2. The method of claim 1, wherein the disease state in the recipient animal is induced experimentally.

3. The method of claim 1, wherein the disease state in the recipient animal is genetic.

4. The method of claim 1, wherein the immune response elicited by the allogeneic donor tissue is any immune response.

5. The method of claim 1, wherein the immune response elicited by the allogeneic donor tissue is rejection of the allogeneic donor tissue.

6. The method of claim 1, wherein the immune response elicited by the allogeneic donor tissue is an inflammatory response.

7. The method of claim 6, wherein the inflammatory response is mediated by interferon-γ

.

8. The method of claim 7, wherein the inflammatory response that is mediated by interferon-γ

is an increase in the expression of MHC class II on the allogeneic donor tissue.

9. The method of claim 7, wherein the inflammatory response that is mediated by interferon-γ

is an increase in the expression of MHC class I and II on the allogeneic donor tissue.

10. The method of claim 1, wherein the administration is altered by altering the amount of allogeneic donor tissue administered to the recipient animal.

11. The method of claim 10, wherein the amount of allogeneic donor tissue per administration is altered.

12. The method of claim 10, wherein the number of administrations of allogenic donor tissue is altered.

13. The method of claim 1, wherein the administration is altered by altering the timing of the administration of the allogeneic donor tissue administered to the recipient animal.

14. The method of claim 13, wherein the timing of the initial administration to the recipient animal is altered.

15. The method of claim 13, wherein the timing of any subsequent administration to the recipient animal is altered.

16. The method of claim 1, wherein the administration is altered by altering the site of the administration of the allogeneic donor tissue administered to the recipient animal.

17. The method of claim 1, wherein the recipient animal is treated with at least one agent that reduces the immune response elicited by the allogeneic donor tissue.

18. The method of claim 17, wherein the recipient animal is treated systemically.

19. The method of claim 17, wherein the recipient animal is treated at the site of administration.

20. The method of claim 17, wherein the recipient animal is treated prior to administration of the allogeneic donor tissue.

21. The method of claim 17, wherein the recipient animal is treated after the administration of the allogeneic donor tissue.

22. The method of claim 1, wherein the allogeneic donor tissue is treated with at least one agent that reduces the immune response elicited by the allogeneic donor tissue.

23. The method of claim 1, wherein the immune response observed in the recipient animal in response to the allogeneic donor tissue is predicted to be the same as the probable immune response observed in the recipient human in response to the allogeneic donor tissue.

24. The method of claim 1, wherein the allogeneic donor tissue obtained from a donor animal is equivalent to the allogeneic donor tissue obtained from a donor human.

25. The method of claim 1, wherein the allogeneic donor tissue comprises cells.

26. The method of claim 25, wherein the cells are umbilicus-derived cells.

27. A method to determine the optimal administration protocol of allogeneic donor tissue to treat a disease in a human, using an animal model of human disease, comprising the steps of:

a. Obtaining allogeneic donor tissue from a donor animal,

b. Inducing a disease state in a recipient animal,

c. Administering the allogeneic donor tissue to the recipient animal, and monitoring the immune response elicited by the allogeneic donor tissue,

d. Monitoring the efficacy of the allogeneic donor tissue in the recipient animal, and

e. Altering the administration of the allogeneic donor tissue to reduce the immune response in the recipient animal.

28. The method of claim 27, wherein the disease state in the recipient animal is induced experimentally.

29. The method of claim 27, wherein the disease state in the recipient animal is genetic.

30. The method of claim 27, wherein the immune response elicited by the allogeneic donor tissue is any immune response.

31. The method of claim 27, wherein the immune response elicited by the allogeneic donor tissue is rejection of the allogeneic donor tissue.

32. The method of claim 27, wherein the immune response elicited by the allogeneic donor tissue is an inflammatory response.

33. The method of claim 32, wherein the inflammatory response is mediated by interferon-γ

.

34. The method of claim 33, wherein the inflammatory response that is mediated by interferon-γ

is an increase in the expression of MHC class II on the allogeneic donor tissue.

35. The method of claim 33, wherein the inflammatory response that is mediated by interferon-γ

is an increase in the expression of MHC class I and II on the allogeneic donor tissue.

36. The method of claim 27, wherein the administration is altered by altering the amount of allogeneic donor tissue administered to the recipient animal.

37. The method of claim 36, wherein the amount of allogeneic donor tissue per administration is altered.

38. The method of claim 36, wherein the number of administrations of allogenic donor tissue is altered.

39. The method of claim 27, wherein the administration is altered by altering the timing of the administration of the allogeneic donor tissue administered to the recipient animal.

40. The method of claim 39, wherein the timing of the initial administration to the recipient animal is altered.

41. The method of claim 39, wherein the timing of any subsequent administration to the recipient animal is altered.

42. The method of claim 27, wherein the administration is altered by altering the site of the administration of the allogeneic donor tissue administered to the recipient animal.

43. The method of claim 27, wherein the recipient animal is treated with at least one agent that reduces the immune response elicited by the allogeneic donor tissue.

44. The method of claim 43, wherein the recipient animal is treated systemically.

45. The method of claim 43, wherein the recipient animal is treated at the site of administration.

46. The method of claim 43, wherein the recipient animal is treated prior to administration of the allogeneic donor tissue.

47. The method of claim 43, wherein the recipient animal is treated after the administration of the allogeneic donor tissue.

48. The method of claim 27, wherein the allogeneic donor tissue is treated with at least one agent that reduces the immune response elicited by the allogeneic donor tissue.

49. The method of claim 27, wherein the immune response observed in the recipient animal in response to the allogeneic donor tissue is predicted to be the same as the probable immune response observed in the recipient human in response to the allogeneic donor tissue.

50. The method of claim 27, wherein the allogeneic donor tissue obtained from a donor animal is equivalent to the allogeneic donor tissue obtained from a donor human.

51. The method of claim 27, wherein the allogeneic donor tissue comprises cells.

52. The method of claim 51, wherein the cells are umbilicus-derived cells.